


# Isothiourea-Catalyzed Enantioselective Synthesis of Tetrahydro- $\alpha$ -carbolinones

Honglei Liu,<sup>a</sup> Alexandra. M. Z. Slawin,<sup>a</sup> Andrew D. Smith<sup>a\*</sup>

<sup>a</sup> EaStCHEM, School of Chemistry, University of St Andrews, North Haugh, St Andrews, Fife, KY16 9ST, UK

Supporting Information Placeholder



**ABSTRACT:** An isothioureacatalyzed enantioselective annulation protocol using indolin-2-imines with a series of  $\alpha,\beta$ -unsaturated *p*-nitrophenyl esters for the synthesis of tetrahydro- $\alpha$ -carbolinones has been developed. Using 5 mol% of the isothioureacatalyst HyperBTM as the Lewis base catalyst, this process allows the enantioselective preparation of a range of C(4)-substituted tetrahydro- $\alpha$ -carbolinones in good to excellent yield and with high enantioselectivity (20 examples, 32-99% yield and up to 99:1 er).


Nitrogen-containing heterocycles are important structural motifs prevalent in a diverse range of natural products and medicinal agents. Their importance is readily quantified as 59% of US FDA approved small-molecule drugs contain a nitrogen heterocycle,<sup>1</sup> with these heterocycles commonly incorporated into molecules to improve physicochemical properties.<sup>2</sup>  $\alpha$ -Carbolines and their tetrahydro- $\alpha$ -carbolinone derivatives (Figure 1A) are a representative class of N-heterocycle that are frequently found in natural compounds with diverse biological activities.<sup>3</sup> Although a range of methods for the construction of  $\beta$ - and  $\gamma$ -carbolinone skeletons has been reported,<sup>4</sup> limited synthetic routes to  $\alpha$ -carbolinones have been developed, with enantioselective methods rare. For example, Zhou and co-workers have developed a sequential Michael addition/amidation/reductive cyclization process using oxindole nucleophiles with Michael acceptors to give tetrahydro- $\alpha$ -carbolinones in racemic form.<sup>5,6</sup> Alternatively, Li and co-workers have demonstrated the enantioselective synthesis of tetrahydro- $\alpha$ -carbolinones through an NHC-catalyzed formal [4+2] cyclization of aza-dienes with an azolium enolate derived from  $\alpha$ -chloroaldehydes.<sup>7</sup> Recently, Ye and co-workers reported an elegant oxidative NHC-catalyzed annulation of indolin-2-imines with *in situ* generation  $\alpha,\beta$ -unsaturated acyl azolium intermediates for the preparation of racemic tetrahydro- $\alpha$ -carbolinones bearing C(4)-aryl and C(4)-alkyl groups (Figure 1B) that served as precedent for this work.<sup>8</sup>

Isothioureas are versatile and powerful Lewis base catalysts of broad synthetic utility,<sup>9</sup> and have been utilized for the *in situ* generation of chiral  $\alpha,\beta$ -unsaturated acyl ammonium species for use in a range of reaction processes.<sup>10</sup> In previous work, we and others have harnessed this intermediate in Michael addition and subsequent lactonization or lactamization processes to generate carbo- and heterocycles.<sup>10a,f,l,m</sup> Building upon these precedents,

this manuscript showcases the use of isothioureacatalysts for the enantioselective synthesis of tetrahydro- $\alpha$ -carbolinones using indolin-2-imines and  $\alpha,\beta$ -unsaturated esters as starting materials (Figure 1C).


## Figure 1. Synthesis of Tetrahydro- $\alpha$ -carbolinones

### A. $\alpha$ -Carbolines and tetrahydro- $\alpha$ -carbolinone derivatives




- Common structural motifs in natural and bioactive compounds
- Few enantioselective methods to prepare  $\alpha$ -carbolinones

### B. Ye: NHC-catalyzed tetrahydro- $\alpha$ -carbolinone synthesis




### C. This work: Isothiourea-catalyzed enantioselective annulation



- Enantioselective annulation to give tetrahydro- $\alpha$ -carbolinones
- Broad scope • Limitations probed • Excellent er

Initial investigations studied the proposed annulation between indolin-2-imine **2** and  $\beta$ -trifluoromethyl  $\alpha,\beta$ -unsaturated *p*-nitrophenyl (PNP) ester **1** using (2*S*,3*R*)-HyperBTM **3** (20 mol %) and an equivalent of  $i\text{Pr}_2\text{NEt}$  in THF at room temperature. The desired C(4)-trifluoromethyl substituted tetrahydro- $\alpha$ -carboline product **6** was afforded in 53% yield with 98:2 er (Table 1, entry 1). Use of alternative isothiourea catalysts (*R*)-BTM **4** and (*S*)-tetramisole hydrochloride **5** gave lower product conversion and yield, despite promising enantioselectivity with BTM (entries 2–3). Further optimisation varied both base and solvent (entries 4–10). Variation of base showed that  $\text{NaHCO}_3$  gave improved yield and excellent er in THF. A screen of solvents showed that an excellent 91% isolated yield of **6** with 97:3 er was observed in acetonitrile (entry 10). Carrying out the reaction without additional base provided a lower isolated yield (65%, entry 11). Decreasing the catalyst loading to 5 mol% gave **6** in still excellent yield and enantioselectivity (entry 12). Finally, improved yield while maintaining high enantioselectivity was observed (up to 99% yield and 97:3 er) when using a small excess (1.2 equiv) of imine **2** at room temperature or at 0 °C (entries 13–14).

**Table 1. Optimization of Reaction Conditions<sup>a</sup>**




entry	cat.	base	solvent	yield (%) <sup>b</sup>	er (%) <sup>c</sup>
1	<b>3</b>	$i\text{Pr}_2\text{NEt}$	THF	53	98:2
2	<b>4</b>	$i\text{Pr}_2\text{NEt}$	THF	37	98:2
3	<b>5</b>	$i\text{Pr}_2\text{NEt}$	THF	6	15:85
4	<b>3</b>	$\text{Et}_3\text{N}$	THF	40	98:2
5	<b>3</b>	$\text{Na}_2\text{CO}_3$	THF	12	>99:1
6	<b>3</b>	$\text{NaHCO}_3$	THF	68	>99:1
7	<b>3</b>	$\text{NaHCO}_3$	toluene	81	98:2
8	<b>3</b>	$\text{NaHCO}_3$	$\text{CH}_2\text{Cl}_2$	80	98:2
9	<b>3</b>	$\text{NaHCO}_3$	dioxane	80	83:17
10	<b>3</b>	$\text{NaHCO}_3$	$\text{CH}_3\text{CN}$	91	97:3
11	<b>3</b>	-	$\text{CH}_3\text{CN}$	65	97:3
12 <sup>d</sup>	<b>3</b>	$\text{NaHCO}_3$	$\text{CH}_3\text{CN}$	83	96:4
13 <sup>d,e</sup>	<b>3</b>	$\text{NaHCO}_3$	$\text{CH}_3\text{CN}$	99	97:3
14 <sup>d,f</sup>	<b>3</b>	$\text{NaHCO}_3$	$\text{CH}_3\text{CN}$	99	97:3

<sup>a</sup> Unless indicated otherwise, reactions were carried out in 1 mL of solvent using 0.1 mmol of **1**, 0.1 mmol of **2**, 0.1 mmol base in the presence of 20 mol% of catalysts **3–5** at rt. <sup>b</sup> Isolated yield given. <sup>c</sup> Determined by HPLC analysis on a chiral stationary phase and given as a ratio of (*S*):(*R*). <sup>d</sup> 5 mol% of **3** used. <sup>e</sup> 0.12 mmol of **2** used. <sup>f</sup> Carried out at 0 °C.

Using the optimal reaction conditions, variation of the C(3)-substituent within the  $\alpha,\beta$ -unsaturated PNP ester to construct C(4)-substituted tetrahydro- $\alpha$ -carboline was explored

(Scheme 1). C(3)-Chlorodifluoromethyl-, -bromodifluoromethyl-, -difluoromethyl-, and -perfluoroethyl-substituted esters gave the corresponding products **18–21** in good to excellent yields and with high enantioselectivity. Notably,<sup>10g</sup> challenging C(3)-aliphatic substituents that are typically recalcitrant when using  $\alpha,\beta$ -unsaturated PNP esters are also tolerated, giving the desired products **22–24** in moderate yield (38–59%) but with excellent enantioselectivity. While the corresponding C(3)-phenyl-substituted ester provided **25** in 53% yield but poor 57:43 er, the use of the corresponding isopropyl carbonic anhydride using  $i\text{Pr}_2\text{NEt}$  as base in THF gave **25** in 40% yield and improved 88:12 er. Other C(3)-substituted esters containing C(3)-ester and C(3)-amide functional groups gave the corresponding products **26–27** in good yield and good to excellent enantioselectivity.

**Scheme 1. Variation of the  $\alpha,\beta$ -Unsaturated Aryl Ester<sup>a</sup>**




<sup>a</sup> Isolated yield given; er determined by HPLC analysis on a chiral stationary phase. <sup>b</sup> Carried out in THF using (*E*)-cinnamic (isopropyl carbonic) anhydride **17** and  $i\text{Pr}_2\text{NEt}$ .

Further work probed the scope of this transformation through structural variation of the N-substituent and aryl substitution pattern within the indolin-2-imine component (Scheme 2). *N*-Benzyl substitution led to decreased yield over the *N*-Me variant, giving **37** in 32% yield but excellent 96:4 er. Aryl substituent variation proved more tolerant to steric and electronic variation, with various indolin-2-imines incorporating both elec-

tron-withdrawing halogen or electron-donating methyl substituents tolerated. Notably, the substitution pattern has an interesting influence on the observed reactivity. 6-Substituted indolin-2-imines gave the products **38** – **39**, **42** and **44** in good 72–76% yield with 95:5–99:1 er. In contrast, incorporation of substituents into the 4-, 5- or 7-position of the indolin-2-imine substrate led to the corresponding products **40**, **41**, **43** and **45** in moderate 37 – 54% yield but with good enantioselectivity (up to 98:2 er).


### Scheme 2. Variation of Indolin-2-imine component<sup>a</sup>



<sup>a</sup> Isolated yield given; er was determined by HPLC analysis on a chiral stationary phase.

The scalability of this process was demonstrated by performing the reaction of indolin-2-imine **2** with β-trifluoromethyl α,β-unsaturated PNP ester **1** on a gram scale, giving **6** in excellent 87% yield and 97:3 er (Scheme 3A). To further demonstrate the utility of the α-carbolinone products, **6** was derivatized to a range of compounds (Scheme 3B). Treatment of **6** with Mg/methanol gave ring-opened product **46** in 99% yield and 97:3 er.<sup>8</sup> Oxidation of **6** with *m*-CPBA gave the corresponding epoxide *in situ*, with subsequent rearrangement yielding spiro lactone **47** as a single diastereoisomer in moderate isolated yield but high er. The absolute configuration of **47** was determined by single crystal X-ray diffraction, which also served to assign the absolute configuration at C(4) within **6**, with all other α-carbolinone products assigned by analogy.<sup>11</sup> Alternatively, sequential reduction with LiAlH<sub>4</sub> and triethylsilane gave tetrahydropyranoindole **48** in 68% yield and 97:3 er,<sup>7</sup> while dehydrogenation of **6** was also readily achieved with Pd/C, giving **49** in 57% yield.<sup>8</sup>

### Scheme 3. Gram-Scale Experiment and Derivatizations



Based upon our previous mechanistic investigations in this area a simple catalytic cycle is proposed (Figure 2).<sup>10a</sup> Catalysis is initiated through rapid and reversible acylation of HyperBTM **3** by the α,β-unsaturated ester **1** to give α,β-unsaturated acyl isothiuronium ion pair **50**. The addition of enamine anion **51**, generated from indoline-2-imine **2**, to the α,β-unsaturated acyl isothiuronium **50** gives isothiuronium enolate **52**. Subsequent proton transfer gives zwitterion **53**. Finally, lactamization yields the product **6** and regenerates the isothioureia HyperBTM **3**. The stereochemical outcome of the reaction can be rationalised by the α,β-unsaturated acyl isothiuronium **50** adopting an *s-cis* conformation, with a 1,5-S···O interaction between the acyl O and catalyst S providing a conformational lock.<sup>12</sup> Enantioselective conjugate addition of the enamine anion to the α,β-unsaturated acyl isothiuronium **50** takes place *anti*- to the stereodirecting pseudo-axial phenyl substituent of the acylated HyperBTM isothioureia catalyst and determines the configuration at C(4)-within the products.




Figure 2. Proposed Mechanism

In conclusion, an isothioureacatalyzed enantioselective annulation protocol of indolin-2-imines with a series of  $\alpha,\beta$ -unsaturated *p*-nitrophenyl esters for the synthesis of tetrahydro- $\alpha$ -carbolinones has been developed. Using 5 mol% of isothioureacatalyst HyperBTM **3**, this protocol allows the enantioselective preparation of a range of C(4)-substituted tetrahydro- $\alpha$ -carbolinones in moderate to excellent yield and with excellent enantioselectivity (20 examples, 32-99% yield and up to 99:1 er). The scope of the process has been demonstrated through variation in both C(3)-substitution within the  $\alpha,\beta$ -unsaturated *p*-nitrophenyl ester, as well as the N-substituent and aryl substitution pattern within the indolin-2-imine component. Further investigations from within our laboratory are concerned with alternative applications of isothiureas and harnessing the utility of  $\alpha,\beta$ -unsaturated acyl ammonium intermediates.<sup>13</sup>

## ASSOCIATED CONTENT

### Supporting Information

The Supporting Information is available free of charge on the ACS Publications website.

Experimental details, compound characterization, NMR spectra, HPLC traces (PDF).

## AUTHOR INFORMATION

### Corresponding Author

\* ads10@st-andrews.ac.uk

### Author Contributions

The manuscript was written by H. L. and A. D. S. All authors have given approval to the final version of the manuscript.

### Notes

The authors declare no competing financial interest.

## ACKNOWLEDGMENT

The research leading to these results has received funding from the Royal Society (Newton Fellowship Programme, H. L.). A.D.S. thanks the Royal Society for a Wolfson Research Merit Award.

## REFERENCES

- (1) Vitaku, E.; Smith, D. T.; J. Njardarson, T. *J. Med. Chem.* **2014**, *57*, 10257.
- (2) Gomtsyan, A. *Chem. Heterocycl. Compd.* **2012**, *48*, 7.
- (3) For selected examples of  $\alpha$ -Carboline derivatives, see: (a) Moquin-Pattay, C.; Guyot, M. *Tetrahedron* **1989**, *45*, 3445. (b) Miyake, F. Y.; Yakushijin, K.; Horne, D. A. *Angew. Chem., Int. Ed.* **2005**, *44*, 3280. (c) Choshi, T.; Yamada, S.; Sugino, E.; Kuwada, T.; Hibino, S. *J. Org. Chem.* **1995**, *60*, 5899. (d) Kim, J.-S.; Shin-ya, K.; Furihata, K.; Hayakawa, Y.; Seto, H. *Tetrahedron Lett.* **1997**, *38*, 3431. (e) Rajanarendar, E.; Govardhan Reddy, K.; Ramakrishna, S.; Nagi Reddy, M.; Shireesha, B.; Durgaiyah, G.; Reddy, Y. N. *Bioorg. Med. Chem. Lett.* **2012**, *22*, 6677. (f) Sharaf, M. H. M.; Schiff, P. L.; Tackie, A. N.; Phoebe, C. H.; Martin, G. E. J. *J. Heterocycl. Chem.* **1996**, *33*, 239. (g) Bolton, D.; Forbes, I. T.; Hayward, C. J.; Piper, D. C.; Thomas, D. R.; Thompson, M.; Upton, N. *Bioorg. Med. Chem. Lett.* **1993**, *3*, 1941. (h) Ueshima, K.; Akihisa-Umeno, H.; Nagayoshi, A.; Takakura, S.; Matsuo, M.; Mutoh, S. *Biol. Pharm. Bull.* **2005**, *28*, 247. (i) Cimanga, K.; De Bruyne, T.; Pieters, L.; Claeys, M.; Vlietinck, A. *Tetrahedron Lett.* **1996**, *37*, 1703. For selected examples of tetrahydro- $\alpha$ -carbolinone derivatives, see: (j) Steyn, P. S. *Tetrahedron* **1970**, *26*, 51. (k) Hirano, A.; Iwai, Y.; Masuma, R.; Tei, K.; Omura, S. *J. Antibiot.* **1979**, *32*, 781. (l) Nozawa, K.; Nakajima, S. *J. Nat. Prod.* **1979**, *42*, 374. (m) Konda, Y.; Onda, M.; Hirano, A.; Omura, S. *Chem. Pharm. Bull.* **1980**, *28*, 2987. (n) Kozlovsky, A. G.; Vinokurova, N. G.; Reshetilova, T. A.; Sakharovsky, V. G.; Baskunov, B. P.; Seleznyov, S. G. *Appl. Biochem. Microbiol.* **1994**, *30*, 410. (o) Nakao, Y.; Yeung, B. K. S.; Yoshida, W. Y.; Scheuer, P. J.; Kelly-Borges, M. *J. Am. Chem. Soc.* **1995**, *117*, 8271. (p) Yeung, B. K. S.; Nakao, Y.; Kinnel, R. B.; Carney, J. R.; Yoshida, W. Y.; Scheuer, P. J. *J. Org. Chem.* **1996**, *61*, 7168. (q) Nakao, Y.; Kuo, J.; Yoshida, W. Y.; Kelly, M.; Scheuer, P. J. *Org. Lett.* **2003**, *5*, 1387. (r) Koizumi, Y.; Arai, M.; Tomoda, H.; Omura, S. *Biochim. Biophys. Acta Mol. Cell Res.* **2004**, *1693*, 47. (s) Overy, D. P.; Phipps, R. K.; Frydenvang, K.; Larsen, T. O. *Biochem. Syst. Ecol.* **2006**, *34*, 345. (t) He, R.; Ding, C.; Maruoka, K. *Angew. Chem. Int. Ed.* **2009**, *48*, 4559. (u) Du, L.; Li, D.; Zhu, T.; Cai, S.; Wang, F.; Xiao, X.; Gu, Q. *Tetrahedron* **2009**, *65*, 1033. (v) Guo, C.; Song, J.; Luo, S.-W.; Gong, L.-Z. *Angew. Chem. Int. Ed.* **2010**, *49*, 5558. (w) Du, L.; Feng, T.; Zhao, B.; Li, D.; Cai, S.; Zhu, T.; Wang, F.; Xiao, X.; Gu, Q. *J. Antibiot.* **2010**, *63*, 165. (x) Luo, S. P.; Peng, Q. L.; Xu, C. P.; Wang, A. E.; Huang, P. Q. *Chin. J. Chem.* **2014**, *32*, 757. (y) Yao, J.; Jiao, R.; Liu, C.; Zhang, Y.; Yu, W.; Lu, Y.; Tan, R. *Biomol. Ther.* **2016**, *24*, 147. (z) Yao, J.; Wei, X.; Lu, Y. *Biochem. Biophys. Res. Commun.* **2016**, *473*, 867. (4) (a) Veale, C. A.; Damewood, J. R.; Jr.; Steelman, G. B.; Bryant, C.; Gomes, B.; Williams, J. *J. Med. Chem.* **1995**, *38*, 86. (b) Beccalli, E. M.; Broggin, G.; Marchesini, A. Rossi, E. *Tetrahedron* **2002**, *58*, 6673. (c) Harris, J. M.; Padwa, A. *Org. Lett.* **2003**, *5*, 4195. (d) Shi, Z.; Cui, Y.; Jiao, N. *Org. Lett.* **2010**, *12*, 2908. (e) Cananzi, S.; Merlini, L.; Artali, R.; Beretta, G. L.; Zaffaroni, N.; Dallavalle, S. *Bioorg. Med. Chem.* **2011**, *19*, 4971. (f) Broggin, G.; Barbera, V.; Beccalli, E. M.; Borsini, E.; Galli, S.; Lanza, G.; Zecchi, G. *Adv. Synth. Catal.* **2012**, *354*, 159. (g) Regina, G. L.; Famigli, V.; Passacantilli, S.; Pelliccia, S.; Punzi, P.; Silvestri, R. *Synthesis* **2014**, *46*, 2093. (h) Reddy, B. V. S.; Ganesh, A. V.; Vani, M.; Murthy, T. R.; Kalivendi, S. V.; Yadav, J. S. *Bioorg. Med. Chem. Lett.* **2014**, *24*, 4501. (i) Gacias, M.; Geron-Navarro, G.; Plotnikov, A. N.; Zhang, G.; Zeng, L.; Kaur, J.; Moy, G.; Rusinova, E.; Rodriguez, Y.; Matikainen, B.; Vincek, A.; Joshua, J.; Casaccia, P.; Zhou, M.-M. *Chem. Biol.* **2014**, *21*, 841. (j) Li, L.; Zhou, B.; Wang, Y.-H.; Shu, C.; Pan, Y.-F.; Lu, X.; Ye, L.-W. *Angew. Chem., Int. Ed.* **2015**, *54*, 8245. (k) Butani, H. H.; Vachhani, D. D.; Bhoya, U. C.; Shah, A. K.; Van der Eycken, E. V. *Eur. J. Org. Chem.* **2015**, 2124. (l) Mondal, B.; Hazra, S.; Panda, T.; Roy, B. *Beilstein J. Org. Chem.* **2015**, *11*, 1360. (m) Miao, B.; Li, S.; Li, G.; Ma, S. *Org. Lett.* **2016**, *18*, 2556. (n) Naik, P. N.; Alkobati, N. A. H.; Kusrkar, R. S. *ARKIVOC* **2015**, 362. (o) Tulichala, R. N. P.; Swamy, K. C. K. *Org. Biomol. Chem.* **2016**, *14*, 4519. (p) Purohit, P.; Pandey, A. K.; Kumar, B.; Chauhan, P. M. S. *RSC Adv.* **2016**, *6*, 21165. (q) Zhang, K.; Xu, X.; Zheng, J.; Yao, H.; Huang, Y.; Lin, A. *Org. Lett.* **2017**, *19*, 2596. (r) Madhavachary, R.; Naveen, N.; Wang, Y.; Wang, Q.; Konstantinidou, M.; Dömling, A. *Eur. J. Org. Chem.* **2018**, 3139. (5) Liu, X.-L.; Zhang, W.-H.; Yao, Z.; Liu, X.-W.; Peng, L.-J.; Zhao, Z.; Lu, Y.; Zhou, Y.; Yuan, W.-C. *Tetrahedron* **2015**, *71*, 9483. (6) Liu, X.-W.; Yao, Z.; Wang, G.-L.; Chen, Z.-Y.; Liu, X.-L.; Tian, M.-Y.; Wei, Q.-D.; Zhou, Y.; Zhang, J.-F. *Synth. Commun.* **2018**, *48*, 1454. (7) Yang, K.-C.; Li, Q.-Z.; Liu, Y.; He, Q.-Q.; Liu, Y.; Leng, H.-J.; Jia, A.-Q.; Ramachandran, S.; Li, J.-L. *Org. Lett.* **2018**, *20*, 7518. (8) Yi, L.; Zhang, Y.; Zhang, Z.-F.; Sun, D.; Ye, S. *Org. Lett.* **2017**, *19*, 2286. (9) For selected reviews see: (a) Vellalath, S.; Romo, D. *Angew. Chem. Int. Ed.* **2016**, *55*, 13934. (b) Merad, J.; Pons, J.-M.; Chuzel, O.; Bressy, C. *Eur. J. Org. Chem.* **2016**, 5589. (10) For selected examples, see: (a) Robinson, E. R. T.; Fallan, C.; Simal, C.; Slawin, A. M. Z.; Smith, A. D. *Chem. Sci.* **2013**, *4*, 2193. (b) Abbasov, M. E.; Hudson, B. M.; Tantillo, D. J.; Romo, D. *J. Am. Chem. Soc.* **2014**, *136*, 4492. (c) Fukata, Y.; Asano, K.; Matsubara, S. *J. Am. Chem. Soc.* **2015**, *137*, 5320. (d) Ahlemeyer, N. A.; Birman, V. B. *Org. Lett.* **2016**, *18*, 3454. (e) Matviitsuk, A.; Taylor, J. E.; Cordes, D. B.; Slawin, A. M.; Smith, A. D. *Chem. Eur. J.* **2016**, *22*, 17748. (f) Robinson, E. R. T.; Walden, D. M.; Fallan, C.; Greenhalgh, M. D.; Cheong, P. H.-Y.; Smith, A. D. *Chem. Sci.* **2016**, *7*, 6919. (g) Matviitsuk, A.;

Greenhalgh, M. D.; Antúnez, D.-J. B.; Slawin, A. M. Z.; Smith, A. D. *Angew. Chem. Int. Ed.* **2017**, *56*, 12282. (h) Abbasov, M. E.; Hudson, B. M.; Kong, W.; Tantillo, D. J.; Romo, D. *Org. Biomol. Chem.* **2017**, *15*, 3179. (i) Abbasov, M. E.; Hudson, B. M.; Tantillo, D. J.; Romo, D. *Chem. Sci.* **2017**, *8*, 1511. (j) Robinson, E. R. T.; Frost, A. B.; Elías-Rodríguez, P.; Smith, A. D. *Synthesis* **2017**, *49*, 409. (k) Van, K. N.; Romo, D. *J. Org. Chem.* **2018**, *83*, 632. (l) Greenhalgh, M. D.; Qu, S.; Slawin, A. M. Z.; Smith, A. D. *Chem. Sci.* **2018**, *9*, 4909. (m) Jin, J.-H.; Li, X.-Y.; Luo, X.; Deng, W.-P. *Tetrahedron* **2018**, *74*, 6804. (n) Shu, C.; Liu, H.; Slawin, A. M. Z.; Carpenter-Warren, C.; Smith, A. D. *Chem. Sci.* **2020**, *11*, 241.

(11) The relative and absolute configuration of **47** was confirmed by X-ray crystallographic analysis followed by HPLC analysis. CCDC 1973369 contain the supplementary crystallographic data for compound **47**. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre.

(12) Non-covalent S $\cdots$ O interactions have recognized importance in medicinal chemistry: (a) Beno, B. R.; Yeung, K.-S.; Bartberger, M. D.; Pennington, L. D.; Meanwell, N. A. *J. Med. Chem.* **2015**, *58*, 4383. (b) Zhang, X.; Gong, Z.; Li, J.; Lu, J. *Chem. Inf. Model.* **2015**, *55*, 2138.

For selected discussions of S $\cdots$ O interactions in isothiourea-catalyzed reactions: (c) Birman, V. B.; Li, X.; Han, Z. *Org. Lett.* **2007**, *9*, 37. (d) Liu, P.; Yang, X.; Birman, V. B.; Houk, K. N. *Org. Lett.* **2012**, *14*, 3288. (e) Greenhalgh, M. D.; Smith, S. M.; Walden, D. M.; Taylor, J. E.; Brice, Z.; Robinson, E. R. T.; Fallan, C.; Cordes, D. B.; Slawin, A. M. Z.; Richardson, H. C.; Grove, M. A.; Cheong, P. H.-Y.; Smith, A. D. *Angew. Chem. Int. Ed.* **2018**, *57*, 3200. (f) Antúnez, D.-J. B.; Greenhalgh, M. D.; Brueckner, A. C.; Walden, D. M.; Elías-Rodríguez, P.; Roberts, P.; Young, B. G.; West, T. H.; Slawin, A. M. Z.; Cheong, P. H.-Y.; Smith, A. D.; *Chem. Sci.* **2019**, *10*, 6162. (g) Young, C. M.; Elmi, A.; Pascoe, D. J.; Morris, R. K.; McLaughlin, C.; Woods, A. M.; Frost, A. B.; de la Houpliere, A.; Ling, K. B.; Smith, T. K.; Slawin, A. M. Z.; Willoughby, P. H.; Cockcroft, S. L.; Smith, A. D. *Angew. Chem. Int. Ed.* **2020**, DOI.org/10.1002/anie.201914421. Also see references 10(b); 10(f); 10(h); 10(i); 10(n). For an excellent discussion on the origin of chalcogen-bonding interactions see: (h) Pascoe, D. J.; Ling, K. B.; Cockcroft, S. L. *J. Am. Chem. Soc.* **2017**, *139*, 15160.

(13) The research data underpinning this publication can be found at DOI: <https://doi.org/10.17630/46afe239-6329-434e-b590-f53fe3f7de66>